Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
Phase of Trial: Phase IV
Latest Information Update: 05 Jul 2017
Price : $35 *
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- 28 Jul 2015 Planned number of patients changed from 300 to 842, as reported by ClinicalTrials.gov.
- 28 Jul 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
- 28 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.